Cadila Pharmaceuticals, based in Ahmedabad, has launched generic versions of sitagliptin in India under the brand names Jankey and Sitenali to treat type 2 diabetes.
Sitagliptin is a drug from the class of DPP-4 inhibitors, and a one-of-its-kind drug for the treatment of high glucose levels in the blood, also known as hyperglycaemia. High blood glucose can lead to life-threatening complications such as atherosclerosis, stroke, heart attack, retinopathy, neuropathy and nephropathy.
The company has also launched Jankey M, a potent combination of Sitagliptin and Metformin. Sitagliptin has a strong clinical profile and the potential to revolutionize the treatment of type 2 diabetes for millions of people who are unable to achieve the targeted blood sugar level with currently available anti-diabetic medications.
